Tag: trends

Vancouver, Canada, June 08, 2026 (GLOBE NEWSWIRE) --

 No deposit bonus casinos are receiving more attention in 2026 as players look for ways to try an online casino before spending their own money. Offers such as 50 no deposit free spins and $200 no deposit bonus 200 free spins real money allow users to test games, review bonus terms, and understand how a casino works before deciding whether to make a deposit.

RENO, Nev., June 08, 2026 (GLOBE NEWSWIRE) -- Ormat Technologies, Inc. (NYSE: ORA) (the “Company” or “Ormat”), a leading geothermal and renewable energy company and the only vertically integrated designer, builder, owner, and operator of geothermal facilities in the world, today announced the Ormega100, a revolutionary new surface power generation unit engineered to deliver higher output than any other binary solution currently on the market. The Ormega100 marks an accelerated opportunity to commercialize and scale its Enhanced Geothermal System (EGS) developments, connecting subsurface development with surface power generation at an accelerated pace.

Miami-based Amazon brand introduces a slant board, two tib bar models, and a forearm rotator for athletes following the methodology popularized by coach Ben Patrick

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido^®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

SAN FRANCISCO, June 07, 2026 (GLOBE NEWSWIRE) -- On May 12, the Science x AI Summit 2026 held in Silicon Valley brought together numerous scientists, AI researchers, and industry institutions. Lim Meng Hoong, founder of MengHoong Intelligent Investment Academy, was invited to participate in the summit and engaged in discussions on the long-term impact of AI on scientific research systems and industrial structures. Unlike previous discussions centered on commercial applications, the summit this year placed greater emphasis on “how AI can drive scientific breakthroughs” and continued to advance international discussions around AI for Science.